Читать книгу Canine and Feline Epilepsy - Luisa De Risio - Страница 248

Luisa De Risio Neurology/ Neurosurgery Unit, Centre for Small Animal Studies, Animal Health Trust, Newmarket, UK

Structural epilepsy is caused by a known and identifiable structural forebrain disorder such as vascular, inflammatory/infectious, traumatic, anomalous/developmental, neoplastic and degenerative diseases. Reported prevalence of structural epilepsy in dogs and cats varies among studies ranging from 25–38% in dogs and 34–87% in cats (Quesnel et al., 1997; Bateman and Parent, 1999; Platt and Haag, 2002; Pákozdy et al., 2008; Schriefl et al., 2008; Zimmermann et al., 2009; Steinmetz et al., 2013). Dogs and cats with structural epilepsy usually present with neurological signs (other than seizures) interictally. However, focal lesions in particular areas of the brain (‘clinically silent regions’), such as olfactory bulb, frontal, and pyriform lobes can result in seizure activity without any other neurological signs. In addition, seizures may be the first clinical sign or the only abnormality the pet owner recognizes, at least initially. The signalment, history, disease onset and course and neuroanatomic localization can help to formulate the most appropriate differential diagnosis list. Diagnostic investigations (see Chapter 10) are aimed at identifying the underlying aetiology of the seizures and, if present, of the other neurological signs. Treatment is aimed at the underlying aetiology of the structural brain disease and seizure control with antiepileptic medications (AEMs). Commonly used first-line AEMs are phenobarbital (PB) and potassium bromide (KBr) (see Chapters 12, 13 and 14). Loading or combination with other AEMs with shorter half-lives (such as levetiracetam or zonisamide, see Chapters 15 and 16) may be required to obtain timely clinical efficacy. New generation AEMs may also be used as first-line monotherapy when PB- or Br-related excessive sedation is a concern (e.g. dogs with brain tumours). The choice and dose of the most appropriate AEM is influenced not only by the underlying disease but also by its possible systemic manifestations or concurrent disorders (e.g. PB is contraindicated in animals with hepatic dysfunction; dose reduction of renally excreted AEMs is necessary in animals with impaired renal function). In addition, interactions between AEMs and treatment of the underlying cause of structural epilepsy have to be considered (e.g. in dogs, PB can alter the pharmacokinetics and as a consequence may decrease therapeutic effect of corticosteroids, cyclosporine, metronidazole and other medications) (see Chapter 13). Animals with structural epilepsy may present with cluster seizures or status epilepticus (Bateman and Parent, 1999; Zimmermann et al., 2009). Detailed information on pathophysiology and management of cluster seizures and status epilepticus are presented in Chapter 23 and 24, respectively.

Disease groups resulting in structural epilepsy are presented in order according to the acronym VITAMIN D.